Compare MEHA & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEHA | PFSA |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.7M |
| IPO Year | N/A | N/A |
| Metric | MEHA | PFSA |
|---|---|---|
| Price | $0.23 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 590.6K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.05 |
| 52 Week High | $0.74 | $4.22 |
| Indicator | MEHA | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 51.18 |
| Support Level | $0.18 | $0.19 |
| Resistance Level | $0.24 | $2.22 |
| Average True Range (ATR) | 0.02 | 0.35 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 80.14 | 27.82 |
Functional Brands Inc operates in the nutraceutical supplement industry. It is a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, brain and memory, sleep, prenatal and urinary. It is focus on end-consumers through different channels that include pharmacies, wholesalers, international distributors and direct-to-consumers sales. The Company has two reportable segments: 1) Kirkman, which sells a range of nutraceuticals, supplements and related products direct to consumers; 2) HT Naturals, which sells a range of hemp products; and 3) Corporate, which generates no revenue. Key revenue is generated from Kirkman.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.